At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 70 target
Drug / intervention
WX390drug
Likely dose
WX390 1.1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT06117540Phase 2RecruitingUpdate OverdueUpdated 19mo ago · Completion was 12mo agoEnrollment Stalled
Long Recruiting
Update Overdue
An Open-label, Single-arm, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of WX390 in Patients With Advanced Solid Tumors
In Brief
A Phase 2 clinical trial evaluating WX390 for Solid Tumor. Currently recruiting, targeting 70 participants across 1 site.
Signals
Enrollment appears stalled
Detailed Summary
The goal of this clinical trial is to evaluate the efficacy and safety of WX390 in patients with advanced solid tumors. The main questions it aims to answer are: * PFS, OS, DoR at week 48; * antitumor effects at week 24 and week 48. Participants will be treated with WX390 orally, and follow the efficacy and safety evaluation according to the protocol.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor
CountriesChina
Collaborators--
Timeline
Phase 2RecruitingOverdue
20222023202420252026
Enrollment StartMay 2021
First PostedNov 2023
Primary CompletionJun 2025
Study CompletionJun 2026
TodayJul 2026
First PostedNov 7, 2023
Enrollment StartMay 11, 2021
Primary CompletionJun 12, 2025
Study CompletionJun 12, 2026
TodayJul 1, 2026
Enrollment to primary: 4.1 yearsPosted 2.6 years ago
Interventions
WX390drug
WX390 tablet, 1.1 mg once a day